GDRXGoodRx Holdings, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−11% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What GDRX's price assumes
GoodRx Holdings, Inc. trades at 88.5× earnings against 46.9× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 46.9 · 1.89× the median: the market pays up for this one
- Price / sales
- 1.28
Price / sales · as of 2026-Q2
- Free cash flow yield
- 16%
Free cash flow yield · Health Information Services median 4.5%
- Growth the price implies
- −11%
Growth the price implies · The price pays for −11% free cash flow growth a year for a decade; the business has delivered +16% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 1.55
- EV / EBITas of 2026-Q2
- 15.9
- EV / salesas of 2026-Q2
- 1.52
- Healthcare median P/E503 names
- 27.9
- Health Information Services median P/E24 names
- 46.9
- Free cash flow, trailing twelve months
- $197M
- Market capitalisation341.1 million shares, counted Jul 28, 2026
- $1.21B
- 3-year revenue growth
- +1.8%
- 3-year free cash flow growth
- +16%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Health Information Services
Ranks #5 of 18 by RyuScore